Table 1

Patient characteristics (N = 400)

CharacteristicNo. (%)
Median patient age at initial treatment, range, years 52 (1-79) 
Patient gender  
 Male 220 (55) 
 Female 180 (45) 
Donor-patient gender combination  
 Female to male 108 (27) 
 Other 292 (73) 
Diagnosis  
 Myeloid malignancy 232 (58) 
 Lymphoid malignancy 154 (39) 
 Other/nonmalignant 14 (4) 
Disease risk at transplantation*  
 Low 136 (34) 
 High 264 (66) 
Conditioning regimen  
 High dose without TBI 137 (34) 
 High dose with TBI 81 (20) 
 Reduced intensity 182 (46) 
Graft source  
 Bone marrow 46 (12) 
 Mobilized blood cells 332 (83) 
 Cord blood 22 (6) 
Donor and HLA type  
 HLA-matched related 147 (37) 
 HLA-matched unrelated 155 (39) 
 HLA antigen or allele-mismatched related 19 (5) 
 HLA antigen or allele-mismatched unrelated 79 (20) 
CharacteristicNo. (%)
Median patient age at initial treatment, range, years 52 (1-79) 
Patient gender  
 Male 220 (55) 
 Female 180 (45) 
Donor-patient gender combination  
 Female to male 108 (27) 
 Other 292 (73) 
Diagnosis  
 Myeloid malignancy 232 (58) 
 Lymphoid malignancy 154 (39) 
 Other/nonmalignant 14 (4) 
Disease risk at transplantation*  
 Low 136 (34) 
 High 264 (66) 
Conditioning regimen  
 High dose without TBI 137 (34) 
 High dose with TBI 81 (20) 
 Reduced intensity 182 (46) 
Graft source  
 Bone marrow 46 (12) 
 Mobilized blood cells 332 (83) 
 Cord blood 22 (6) 
Donor and HLA type  
 HLA-matched related 147 (37) 
 HLA-matched unrelated 155 (39) 
 HLA antigen or allele-mismatched related 19 (5) 
 HLA antigen or allele-mismatched unrelated 79 (20) 

TBI, total body irradiation.

*

The low-risk category included chronic myeloid leukemia in chronic phase, acute leukemia in first remission, myelodysplastic syndrome without excess blasts, and nonmalignant diseases. The high-risk category included all other diseases and stages.

or Create an Account

Close Modal
Close Modal